InterMune, Inc. (Nasdaq: ITMN) announced that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune’s investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. NicOx announces FDA Advisory Committee to discuss naproxcinod on May 12
2. Sorin Group Announces U.S. FDA Clearance Of Newest Generation Heart Lung-Machine
3. Surescripts Announces Health Information Exchange Advisory Committee
4. FDA Sets March 22 For ODAC Meeting To Review CTI’s New Drug Application For Pixantrone
5. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)